Mel Mann Highlights First Patient Enrollment in AACR-ADOPT-GEA Trial
oncodaily - Mel Mann, World’s Longest Living Gleevec (Imatinib) / TKI Survivor, 31-year terminal Chronic Myeloid Leukemia (CML) Survivor, Clinical Trial Pioneer, and Patient Advocate, shared American Association for Cancer Research (AACR) […]
AI Summary: The AACR‑affiliated ADOPT‑GEA phase II trial for locally advanced gastroesophageal cancer has reported its first patient enrollment, marking a key milestone in the study's launch. The enrollment signals trial readiness and opens recruitment momentum to evaluate investigational approaches for a challenging cancer subtype, advancing potential new treatment options toward evidence‑based use.
FDA approves first drug for full range of narcolepsy symptoms
medicalxpress - The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved…
AI Summary: The FDA has approved a medication that treats the full range of narcolepsy symptoms, including excessive daytime sleepiness and cataplexy, marking the first such comprehensive option for patients with narcolepsy type 1. Clinicians now have a single, regulated choice to address multiple debilitating symptoms rather than juggling piecemeal therapies.
NCCS Develops AI Tool to Predict Liver Cancer Recurrence After Surgery
oncodaily - National Cancer Centre Singapore (NCCS) shared on LinkedIn: “Can we now predict who’s at greatest risk for liver cancer recurrence? Congratulations to NCCS’ Professor Pierce Chow, Associate Professor Wai Leong Tam, Mr. Karthik Sekar, […]
AI Summary: A newly developed AI model predicts risk of liver cancer recurrence following surgical resection, integrating imaging and clinical variables to stratify patients more accurately. Early validation suggests the tool could personalize surveillance intensity and adjuvant therapy decisions, reducing unnecessary exams for low‑risk patients while focusing resources where recurrence risk is highest.
Some COVID-19 Patients Suffered Heart Damage, an Overlooked Coronavirus Protein May Explain Why
discovermagazine - Discover how the inconspicuous nucleocapsid protein from coronaviruses can trigger hyperinflammation, an effect not typically seen in other viruses.
AI Summary: Scientists identified a previously underappreciated SARS‑CoV‑2 protein that appears to damage heart tissue and may help explain persistent post‑COVID symptoms. The study ties the viral molecule to mechanisms of cardiac injury, opening diagnostic and therapeutic research paths for long COVID cardiac effects — proof that sometimes the troublemaker was hiding in plain sight.
International project delivers hundreds of next-generation models for cancer research
medicalxpress - Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available to scienti…
AI Summary: An international consortium released hundreds of patient‑derived tumor models, including a public HCMI set of 665 organoids, creating a living biobank for drug discovery. Labs worldwide now gain access to diverse, next‑generation models to test therapies and probe cancer vulnerabilities — a major boost for preclinical translational work.
- Experts react: three Nature papers and model summaries (3)
- HCMI release: 665 organoids unveiled in Nature (4)
- Organoids power maps and predictors of therapy resistance (4)
Experts react: three Nature papers and model summaries
HCMI release: 665 organoids unveiled in Nature
Organoids power maps and predictors of therapy resistance
Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
Frank Vinluan / medcitynews - Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev,…
AI Summary: After two previous turns in the penalty box, the FDA granted accelerated approval to Replimune’s oncolytic immunotherapy Tudriqev (RP1) in combination with nivolumab for advanced melanoma. The decision follows a favorable advisory committee outcome and positions a once-spurned viral-based therapy back into the clinic as a new option for patients with limited choices.
- Clinical community reaction and rollout: experts and training (4)
- Regulatory comeback: FDA approves Tudriqev after two rejections (4)
- Replimune announcements and company leadership reactions (3)
- All Other Stories
Clinical community reaction and rollout: experts and training
Regulatory comeback: FDA approves Tudriqev after two rejections
Replimune announcements and company leadership reactions
All Other Stories
FDA approves Moderna’s mRNA flu vaccine
Ella Jeffries / beckershospitalreview - The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s …
AI Summary: The FDA has approved Moderna's mRNA flu vaccine, giving the familiar seasonal bug a high-tech reboot. Regulators cleared Moderna’s mRNA formulation for public use, signaling a shift toward next-generation influenza vaccines; rollout details, target groups and supply plans will follow as public health authorities coordinate distribution for the coming flu season.
- FDA's reversal and approval of Moderna mRNA flu shot (3)
- Public health guidance and flu season preparedness (3)
- What mFLUSIVA approval means for policy, coverage and mRNA (3)
FDA's reversal and approval of Moderna mRNA flu shot
Public health guidance and flu season preparedness
What mFLUSIVA approval means for policy, coverage and mRNA
Swallowing faecal capsules reduces peanut allergy in six adults
Alice Klein / newscientist - Altering the gut microbiomes of people with peanut allergy using faeces donated from an allergy-free individual improved their peanut tolerance in a clinical trial
AI Summary: A small human trial showed swallowing fecal microbiota capsules reduced peanut allergy responses in six adults, while parallel animal and mechanistic work implicates bile-acid metabolites in restoring oral tolerance. The findings revive interest in microbiome-based desensitization, though larger trials are required before anyone starts prescribing ‘poop pills’ as routine therapy.
There are new blood tests for Alzheimer's. Should I have one?
medicalxpress - Australians have seen a flurry of headlines announcing the arrival of blood tests for Alzheimer's disease.
AI Summary: New blood tests detecting Alzheimer’s biomarkers are reaching clinical availability, promising earlier and less invasive diagnosis. Clinicians and consumers now face decisions about who should be tested, how to interpret results, and what interventions — if any — follow a positive biomarker. The tests shift diagnostic practice while raising ethical and counseling challenges.
This amino acid may help the body fight tumors and viral infections
medicalxpress - The amino acid arginine helps keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes. It's produced by our bodies and found in common high-protein foods. Low levels of arginine are associated with a…
AI Summary: New research implicates the amino acid histidine in modulating immune and tumor biology, suggesting it may enhance anti-tumor responses and antiviral defenses in preclinical studies. Scientists report mechanistic insights that could inform future therapeutic strategies, although translation to patients will require careful testing—because promising mouse data still need to pass the human audit.
Ancient Smallpox DNA Hidden in Two Chilean Mummies Traces the Disease’s Colonial Arrival
discovermagazine - Learn how centuries-old DNA linked an extinct virus to European colonization and its spread through an Indigenous community in northern Chile.
AI Summary: Researchers detected ancient smallpox DNA in two Chilean mummies, providing genomic evidence that European colonists introduced the virus to the Americas. The findings link historical outbreaks to colonial contact, illuminate pathogen spread centuries ago, and offer a tangible genetic record of the devastating diseases that reshaped indigenous populations.
HHS to stop funding ‘dangerous’ life sciences research
Paige Twenter / beckershospitalreview - The federal government will stop funding what it determines to be “dangerous” gain-of-function research conducted in the U.S. and abroad after implementing a new policy. The “Policy for Stopping High-Risk Life Sciences Research” lands during broader uphea…
AI Summary: The federal government announced a new policy curbing federal funding for defined categories of high‑risk life‑sciences research, citing biosafety and biosecurity concerns. The move pauses support for experiments judged to pose elevated pandemic or containment risks, sparking debate about how to balance oversight, scientific progress and public safety without stifling useful innovation.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.
Ebola Outbreak Surpasses 3,000 Cases as First Human Vaccine Trial for Rare Bundibugyo Virus Begins
discovermagazine - Learn how a rare Ebola strain has fueled one of the largest outbreaks on record and what the first human vaccine trial could mean for containing the outbreak.
AI Summary: An Ebola outbreak in eastern DR Congo has surpassed 3,000 reported cases and is poised to become the second-largest on record. Authorities have launched the first human vaccine trial targeting the Bundibugyo strain while laboratory tests show stockpiled Ebola vaccines generate antibodies against Bundibugyo, intensifying both response operations and urgent vaccine research.
- Race for a Bundibugyo vaccine: trials and lab progress (5)
- Strained response: strikes, unpaid staff, funding and leadership shake-up (5)
- Surging outbreak: cases, deaths and WHO alarm (7)
- All Other Stories
Race for a Bundibugyo vaccine: trials and lab progress
Strained response: strikes, unpaid staff, funding and leadership shake-up
Surging outbreak: cases, deaths and WHO alarm
All Other Stories
FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress
Steve Schneible / aacr - At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how this new Initiative will marshal global…
AI Summary: The AACR has unveiled a Rare Cancers Initiative to coordinate researchers, streamline data sharing, and speed therapeutic development for uncommon tumor types. By pooling expertise, funding and networks, the program seeks to overcome the chronic scarcity of trials and resources that leave rare‑cancer patients waiting for attention that’s been hard to come by.
Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Breathalyzer can 'sniff out' when your body starts burning fat
medicalxpress - Researchers have developed a breath detector with a chemical sensor that sniffs out when your body is burning fat through a single exhale. Reporting in Device, the handheld, smartphone-assisted device measures acetone—a molecule that is released into the …
AI Summary: Engineers developed a breath-based detector that pinpoints when the body shifts to fat oxidation, and shrank it down to a phone-compatible breathalyser. The device measures volatile markers in exhaled breath to indicate metabolic state, enabling noninvasive, real‑time monitoring of fat burning for weight-loss or metabolic research — because your phone now judges your dinner choices.
Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.